# Characteristics, management and factors associated with poor outcomes in COVID-19 patients in Burkina Faso: insights from a 2021 large-scale ambispective study

**Authors:** Ariane Mamguem Kamga, Samiratou Ouédraogo, Firmin Nongodo Kaboré, Isidore Tiandiogo Traoré, Esperance Ouédraogo, Armel Poda, Arnaud Eric Diendéré, Dramane Kania, Hermann Badolo, Guillaume Sanou, Amariane Koné, Therese Samdapawindé Kagoné, Blahima Konaté, Rachel Médah, Nathalie de Rekeneire, Boukary Ouédraogo, Oumar Billa, Gilles Paradis, Halidou Tinto, Tienhan Sandrine Dabakuyo-yonli

PMC · DOI: 10.3389/fpubh.2025.1542024 · 2025-07-10

## TL;DR

This study in Burkina Faso found that age, residence, and comorbidities are linked to worse outcomes in COVID-19 patients.

## Contribution

The study provides insights into risk factors for severe outcomes in a West African population.

## Key findings

- Most patients recovered without complications, with only 5.2% experiencing complications and 3.3% dying.
- Age, urban residence, and comorbidities were identified as significant predictors of poor outcomes.
- The majority of patients were treated with Azithromycin-hydroxychloroquine.

## Abstract

To assess treatment and identify predictive factors of worsening in COVID-19 patients.

This study was ambispective (both prospective and retrospective) and part of a multidisciplinary, multicenter project designed to generate epidemiological, sociological and anthropological data about the COVID-19 epidemic in Burkina Faso. Medical records of patients admitted for COVID-19 at the hospitals of Ouagadougou and Bobo-Dioulasso from March 2020 to April 2021 were reviewed. To identify predictive factors of severe complications, we used Poisson regression models.

In total, 1,511 patients were included, of whom 70% were aged ≤50 years, 59% were men and 97% were living in an urban area. Of the 86% of patients treated, 92.9% of them received the combo Azithromycin-hydroxychloroquine. A total of 78 (5.2%) patients experienced complications during hospitalization, and 49 (3.3%) patients died. Multivariate analysis identified patient's age, residence and comorbidity as factors associated with poor outcomes.

Although most people had symptoms, most of them recovered without sequelae, and few patients had severe forms of disease. Age was a strong predictor of worse outcomes in this population.

## Linked entities

- **Chemicals:** Azithromycin (PubChem CID 447043), hydroxychloroquine (PubChem CID 3652)
- **Diseases:** COVID-19 (MONDO:0100096)

## Full-text entities

- **Diseases:** COVID-19 (MESH:D000086382), died (MESH:D003643)
- **Chemicals:** hydroxychloroquine (MESH:D006886), Azithromycin (MESH:D017963)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12287085/full.md

---
Source: https://tomesphere.com/paper/PMC12287085